טוען...
Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy
Antibody therapy targeting cytotoxic T lymphocyte–associated antigen 4 (CTLA4) elicited survival benefits in cancer patients; however, the overall response rate is limited. In addition, anti-CTLA4 antibody therapy induces a high rate of immune-related adverse events. The underlying factors that may...
שמור ב:
| הוצא לאור ב: | Sci Adv |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
American Association for the Advancement of Science
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5435412/ https://ncbi.nlm.nih.gov/pubmed/28560327 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/sciadv.1602133 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|